Researchers discover link between expression of GATM and pain associated with statins

August 29, 2013 by Bob Yirka report

(Medical Xpress)—A large team with members from several research institutions across the U.S. has found a possible link between the expression of the gene for glycine amidinotransferase (GATM) and pain experienced by patients who take statins to help lower their cholesterol levels. In their paper published in the journal Nature, the team describes their findings and what it might mean for patients in the near future.

People across the world are prescribed statins to help lower levels of cholesterol in their blood—the hope is that such a reduction will reduce the risk of heart attack and stroke. Statins generally do their work on the liver, helping to prevent cholesterol from being released into the bloodstream. In many instances, however, the use of statins in patients has led to muscle pain (known as ) and an increased risk of developing Type II diabetes. In this new effort the researchers sought to learn if there might be a genetic difference between patients who experience pain when using statins and those who do not.

Rather than looking for in the livers of patients, the researchers used lymphoblastoid cell lines that had been obtained from a patients prescribed simvastatin (Zocor) as part of trial testing—lymphoblastoids are a type of immune cell that can serve as a proxy for .

The researchers treated the cells they had obtained with the statin and then searched for changes to expressions by genes that were impacted. After much work, the team began to focus on GATM—it's involved in synthesizing creatine which is known to serve as food for muscles, particularly those that work with the skeletal system. Once GATM had been identified as a possible source, the researchers looked at of statin prescribed patients to see if they could find a link. Sure enough, those that had experienced pain also had different levels of creatine in their muscles than those that did not. Subsequent tests revealed that if GATM levels were artificially reduced, liver cell response was changed, though the researchers still aren't clear as to whether that would lead to less pain in patients.

The researchers note that while their research thus far has found a link between GATM levels and muscle pain, much more work will need to be done to determine if a way can be found to use that knowledge to reduce the painful side effects of statins in some patients.

Explore further: Cholesterol medicine affects energy production in muscles

More information: A statin-dependent QTL for GATM expression is associated with statin-induced myopathy, Nature (2013) DOI: 10.1038/nature12508

Abstract
Statins are prescribed widely to lower plasma low-density lipoprotein (LDL) concentrations and cardiovascular disease risk and have been shown to have beneficial effects in a broad range of patients. However, statins are associated with an increased risk, albeit small, of clinical myopathy and type 2 diabetes. Despite evidence for substantial genetic influence on LDL concentrations, pharmacogenomic trials have failed to identify genetic variations with large effects on either statin efficacy or toxicity, and have produced little information regarding mechanisms that modulate statin response. Here we identify a downstream target of statin treatment by screening for the effects of in vitro statin exposure on genetic associations with gene expression levels in lymphoblastoid cell lines derived from 480 participants of a clinical trial of simvastatin treatment7. This analysis identified six expression quantitative trait loci (eQTLs) that interacted with simvastatin exposure, including rs9806699, a cis-eQTL for the gene glycine amidinotransferase (GATM) that encodes the rate-limiting enzyme in creatine synthesis. We found this locus to be associated with incidence of statin-induced myotoxicity in two separate populations (meta-analysis odds ratio = 0.60). Furthermore, we found that GATM knockdown in hepatocyte-derived cell lines attenuated transcriptional response to sterol depletion, demonstrating that GATM may act as a functional link between statin-mediated lowering of cholesterol and susceptibility to statin-induced myopathy.

Related Stories

Cholesterol medicine affects energy production in muscles

January 3, 2013
Up to 75 per cent of patients who take statins to treat elevated cholesterol levels may suffer from muscle pain. Scientists at the Center for Healthy Aging at the University of Copenhagen have now identified a possible mechanism ...

Anti-cholesterol drugs may do more harm than good for older people

June 3, 2013
The side effects of Australia's most commonly prescribed cholesterol-lowering drugs may outweigh the benefits in older people, a new clinical review has found.

Research looks into lessening the danger of cholesterol-lowering statin drugs

August 6, 2013
Statins, a class of drugs used to lower cholesterol, are among the best selling drugs in North America and around the world. However, statin myopathy, which results in muscle pain and weakness, is a common side effect affecting ...

Cholesterol-lowering drug may reduce exercise benefits for obese adults, study finds

May 15, 2013
Statins, the most widely prescribed drugs worldwide, are often suggested to lower cholesterol and prevent heart disease in individuals with obesity, diabetes and metabolic syndrome, which is a combination of medical disorders ...

Statin use linked to few side effects

July 9, 2013
the popular class of cholesterol-lowering drugs used widely to prevent recurrent heart disease or stroke as well as risk for having a first cardiac or stroke event—appear to cause few side effects, according to new research ...

Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes

April 10, 2013
(Medical Xpress)—A laboratory study has shown for the first time that coenzyme Q10 offsets the cellular changes that are linked to a side-effect of some statin drugs - an increased risk of adult-onset diabetes.

Recommended for you

Researchers investigate the potential of spider silk protein for engineering artificial heart

August 18, 2017
Ever more people are suffering from cardiac insufficiency, despite significant advances in preventing and minimising damage to the heart. The main cause of reduced cardiac functionality lies in the irreversible loss of cardiac ...

Lasers used to detect risk of heart attack and stroke

August 18, 2017
Patients at risk of heart attacks and strokes may be spotted earlier thanks to a diagnosis tool that uses near-infrared light to identify high-risk arterial plaques, according to research carried out at WMG, University of ...

How Gata4 helps mend a broken heart

August 15, 2017
During a heart attack, blood stops flowing into the heart; starved for oxygen, part of the heart muscle dies. The heart muscle does not regenerate; instead it replaces dead tissue with scars made of cells called fibroblasts ...

Injectable tissue patch could help repair damaged organs

August 14, 2017
A team of U of T Engineering researchers is mending broken hearts with an expanding tissue bandage a little smaller than a postage stamp.

'Fat but fit' are at increased risk of heart disease

August 14, 2017
Carrying extra weight could raise your risk of heart attack by more than a quarter, even if you are otherwise healthy.

Air pollution linked to cardiovascular disease; air purifiers may lessen impact

August 14, 2017
Exposure to high levels of air pollution increased stress hormone levels and negative metabolic changes in otherwise healthy, young adults in a recent study conducted in China. Air purifiers appeared to lessen the negative ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.